Skip to Content
 
Jill  Gilbert

Jill Gilbert, M.D.

Associate Professor of Medicine (Hematology/Oncology)
Director, Hematology/Oncology Fellowship Program

  • Appointments
    615-936-8422
    Physicians: 1-877-936-8422
  • Clinical Trials Information
  • Other Telephone Numbers
    Henry-Joyce Cancer Clinic
    (615) 936-8422 or 1 (877) 936-8422

    Office
    615-343-4677
  • Faxes
    Henry-Joyce Cancer Clinic Fax
    (615) 343-8668
    Office Fax
    615-343-7602
  • Addresses
    Henry-Joyce Cancer Clinic
    1301 Medical Center Drive, Suite 1710
    Nashville, Tennessee 37232-7415
    Website

    Office
    Vanderbilt University Medical Center
    777 Preston Research Building
    2220 Pierce Avenue
    Nashville, TN 37232-6307
Profile

Dr. Gilbert is a medical oncologist who specializes in head and neck cancer as well as thyroid cancer. She will primarily be involved in developing clinical trials of novel therapeutic agents for therapy of head and neck and thyroid cancers. Additionally, she is interested in the host immune response in the head and neck cancer survivor and in patients with advanced disease who receive molecularly targeted agents.

As Director of the Hematology/Oncology Fellowship Program, she is extensively involved in training physicians to become specialists in hematology and oncology. In this role, Dr. Gilbert develops and oversees a training program that includes all aspects of clinical hematology/oncology and laboratory-based research opportunities.

Education
  • University of North Carolina, Chapel Hill, North Carolina, BSBiology, May 1990
  • University of Alabama at Birmingham School of Medicine, Magna CumLaude, MD, June 1994
  • Internship, Internal Medicine, University of Alabama atBirmingham, July 1995
  • Residency, Internal Medicine, University of Alabama atBirmingham, July 1997
  • Chief Medical Resident, University of Alabama at Birmingham, May1998
  • Fellow, Medical Oncology and Hematology, Johns Hopkins School ofMedicine, July 2001
Publications
  • Ghiam MK, Mannion K, Dietrich MS, Stevens KL, Gilbert J, Murphy BA. Assessment of musculoskeletal impairment in head and neck cancer patients. Support Care Cancer [print-electronic]. 2017 Jul; 25(7): 2085-92. PMID: 28191589, PII: 10.1007/s00520-017-3603-1, DOI: 10.1007/s00520-017-3603-1, ISSN: 1433-7339.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28191589.
  • Adelstein D, Gillison ML, Pfister DG, Spencer S, Adkins D, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Eisele DW, Fenton M, Foote RL, Gilbert J, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Leizman D, Lydiatt WM, Maghami E, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rocco J, Rodriguez CP, Shah JP, Weber RS, Witek M, Worden F, Yom SS, Zhen W, Burns JL, Darlow SD. NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2017. J Natl Compr Canc Netw. 2017 Jun; 15(6): 761-70. PMID: 28596256, PII: 15/6/761, DOI: 10.6004/jnccn.2017.0101, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28596256.
  • Bauml J, Seiwert TY, Pfister DG, Worden F, Liu SV, Gilbert J, Saba NF, Weiss J, Wirth L, Sukari A, Kang H, Gibson MK, Massarelli E, Powell S, Meister A, Shu X, Cheng JD, Haddad R. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. J. Clin. Oncol [print-electronic]. 2017 May 5/10/2017; 35(14): 1542-9. PMID: 28328302, DOI: 10.1200/JCO.2016.70.1524, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28328302.
  • Goff LW, Cardin DB, Whisenant JG, Du L, Koyama T, Dahlman KB, Salaria SN, Young RT, Ciombor KK, Gilbert J, Smith SJ, Chan E, Berlin J. A phase I trial investigating pulsatile erlotinib in combination with gemcitabine and oxaliplatin in advanced biliary tract cancers. Invest New Drugs [print-electronic]. 2017 Feb; 35(1): 95-104. PMID: 27853997, PMCID: PMC5306261, PII: 10.1007/s10637-016-0406-z, DOI: 10.1007/s10637-016-0406-z, ISSN: 1573-0646.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27853997.
  • Marur S, Li S, Cmelak AJ, Gillison ML, Zhao WJ, Ferris RL, Westra WH, Gilbert J, Bauman JE, Wagner LI, Trevarthen DR, Balkrishna J, Murphy BA, Agrawal N, Colevas AD, Chung CH, Burtness B. E1308: Phase II Trial of Induction Chemotherapy Followed by Reduced-Dose Radiation and Weekly Cetuximab in Patients With HPV-Associated Resectable Squamous Cell Carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group. J. Clin. Oncol [print-electronic]. 2016 Dec 12/28/2016; JCO2016683300. PMID: 28029303, PMCID: PMC5455313, PII: 10.1200/JCO.2016.68.3300, DOI: 10.1200/JCO.2016.68.3300, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/28029303.
  • Bond SM, Dietrich MS, Gilbert J, Ely EW, Jackson JC, Murphy BA. Neurocognitive function in patients with head and neck cancer undergoing primary or adjuvant chemoradiation treatment. Support Care Cancer [print-electronic]. 2016 Oct; 24(10): 4433-42. PMID: 27225527, PII: 10.1007/s00520-016-3284-1, DOI: 10.1007/s00520-016-3284-1, ISSN: 1433-7339.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27225527.
  • Jackson LK, Ridner SH, Deng J, Bartow C, Mannion K, Niermann K, Gilbert J, Dietrich MS, Cmelak AJ, Murphy BA. Internal Lymphedema Correlates with Subjective and Objective Measures of Dysphagia in Head and Neck Cancer Patients. J Palliat Med [print-electronic]. 2016 Sep; 19(9): 949-56. PMID: 27227341, PMCID: PMC5011629, DOI: 10.1089/jpm.2016.0018, ISSN: 1557-7740.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27227341.
  • Weiss J, Grilley Olson J, Deal AM, Chera B, Weissler M, Murphy BA, Hayes DN, Gilbert J. Using the galactose-a-1,3-galactose enzyme-linked immunosorbent assay to predict anaphylaxis in response to cetuximab. Cancer [print-electronic]. 2016 Jun 6/1/2016; 122(11): 1697-701. PMID: 26989991, DOI: 10.1002/cncr.29978, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26989991.
  • Jackson LK, Deng J, Ridner SH, Gilbert J, Dietrich MS, Murphy BA. Preliminary Testing of a Patient-Reported Outcome Measure for Recurrent or Metastatic Head and Neck Cancer. Am J Hosp Palliat Care [print-electronic]. 2016 May; 33(4): 313-20. PMID: 25667146, PII: 1049909115569591, DOI: 10.1177/1049909115569591, ISSN: 1938-2715.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25667146.
  • Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol [print-electronic]. 2016 Feb; 53: 54-9. PMID: 26705063, PMCID: PMC4707116, PII: S1368-8375(15)00398-X, DOI: 10.1016/j.oraloncology.2015.11.020, ISSN: 1879-0593.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26705063.
  • Wong SJ, Karrison T, Hayes DN, Kies MS, Cullen KJ, Tanvetyanon T, Argiris A, Takebe N, Lim D, Saba NF, Worden FP, Gilbert J, Lenz HJ, Razak AR, Roberts JD, Vokes EE, Cohen EE. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Ann. Oncol [print-electronic]. 2016 Feb; 27(2): 318-23. PMID: 26598548, PMCID: PMC4722891, PII: mdv537, DOI: 10.1093/annonc/mdv537, ISSN: 1569-8041.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26598548.
  • Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open. 2016; 1(5): e000097. PMID: 27843641, PMCID: PMC5070299, PII: esmoopen-2016-000097, DOI: 10.1136/esmoopen-2016-000097, ISSN: 2059-7029.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/27843641.
  • Pfister DG, Spencer S, Brizel DM, Burtness B, Busse PM, Caudell JJ, Cmelak AJ, Colevas AD, Dunphy F, Eisele DW, Foote RL, Gilbert J, Gillison ML, Haddad RI, Haughey BH, Hicks WL, Hitchcock YJ, Jimeno A, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mell LK, Mittal BB, Pinto HA, Ridge JA, Rodriguez CP, Samant S, Shah JP, Weber RS, Wolf GT, Worden F, Yom SS, McMillian N, Hughes M. Head and Neck Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Jul; 13(7): 847-55; quiz 856. PMID: 26150579, PMCID: PMC4976490, PII: 13/7/847, ISSN: 1540-1413.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/26150579.
  • Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin. Cancer Res [print-electronic]. 2015 Apr 4/1/2015; 21(7): 1566-73. PMID: 25573383, PII: 1078-0432.CCR-14-2820, DOI: 10.1158/1078-0432.CCR-14-2820, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25573383.
  • Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol [print-electronic]. 2015 Apr; 16(4): 426-35. PMID: 25795408, PII: S1470-2045(15)70081-1, DOI: 10.1016/S1470-2045(15)70081-1, ISSN: 1474-5488.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25795408.
  • Gilbert J, Schell MJ, Zhao X, Murphy B, Tanvetyanon T, Leon ME, Neil Hayes D, Haigentz M, Saba N, Nieva J, Bishop J, Sidransky D, Ravi R, Bedi A, Chung CH. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncol [print-electronic]. 2015 Apr; 51(4): 376-82. PMID: 25593015, PMCID: PMC4459134, PII: S1368-8375(14)00383-2, DOI: 10.1016/j.oraloncology.2014.12.011, ISSN: 1879-0593.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25593015.
  • Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J, Poondru S, Simantov R, Gedrich R, Stephens A, Chan E, Evans TR. A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin. Cancer Res [print-electronic]. 2015 Feb 2/15/2015; 21(4): 701-11. PMID: 25212606, PII: 1078-0432.CCR-14-0303, DOI: 10.1158/1078-0432.CCR-14-0303, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25212606.
  • Gilbert J, Chew H, Dewey C, Horn L. Medical education: perils and progress in educating and assessing a new generation of learners. Am Soc Clin Oncol Educ Book. 2015; 33-9. PMID: 25993139, PII: 00115000033, DOI: 10.14694/EdBook_AM.2015.35.33, ISSN: 1548-8756.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25993139.
  • Chung CH, Lee JW, Slebos RJ, Howard JD, Perez J, Kang H, Fertig EJ, Considine M, Gilbert J, Murphy BA, Nallur S, Paranjape T, Jordan RC, Garcia J, Burtness B, Forastiere AA, Weidhaas JB. A 3'-UTR KRAS-variant is associated with cisplatin resistance in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol [print-electronic]. 2014 Nov; 25(11): 2230-6. PMID: 25081901, PMCID: PMC4207729, PII: mdu367, DOI: 10.1093/annonc/mdu367, ISSN: 1569-8041.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/25081901.
  • Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W. Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel. Oncologist [print-electronic]. 2014 Jun; 19(6): 616-22. PMID: 24797823, PMCID: PMC4041676, PII: theoncologist.2014-0011, DOI: 10.1634/theoncologist.2014-0011, ISSN: 1549-490X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24797823.
  • Gregg JR, Horn L, Davidson MA, Gilbert J. Patient enrollment onto clinical trials: the role of physician knowledge. J Cancer Educ. 2014 Mar; 29(1): 74-9. PMID: 24163050, DOI: 10.1007/s13187-013-0548-z, ISSN: 1543-0154.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/24163050.
  • Hamm HE, Kaya AI, Gilbert JA, Preininger AM. Linking receptor activation to changes in Sw I and II of Ga proteins. J. Struct. Biol [print-electronic]. 2013 Oct; 184(1): 63-74. PMID: 23466875, PMCID: PMC3726552, PII: S1047-8477(13)00053-1, DOI: 10.1016/j.jsb.2013.02.016, ISSN: 1095-8657.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/23466875.
  • Deng J, Murphy BA, Dietrich MS, Wells N, Wallston KA, Sinard RJ, Cmelak AJ, Gilbert J, Ridner SH. Impact of secondary lymphedema after head and neck cancer treatment on symptoms, functional status, and quality of life. Head Neck [print-electronic]. 2013 Jul; 35(7): 1026-35. PMID: 22791550, PMCID: PMC4017911, DOI: 10.1002/hed.23084, ISSN: 1097-0347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22791550.
  • Gilbert J, Lee JW, Argiris A, Haigentz M, Feldman LE, Jang M, Arun P, Van Waes C, Forastiere AA. Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of the head and neck (E1304): a trial of the Eastern Cooperative Oncology Group. Head Neck [print-electronic]. 2013 Jul; 35(7): 942-8. PMID: 22791234, PMCID: PMC3689864, DOI: 10.1002/hed.23046, ISSN: 1097-0347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22791234.
  • Cummings AC, Jiang L, Velez Edwards DR, McCauley JL, Laux R, McFarland LL, Fuzzell D, Knebusch C, Caywood L, Reinhart-Mercer L, Nations L, Gilbert JR, Konidari I, Tramontana M, Cuccaro ML, Scott WK, Pericak-Vance MA, Haines JL. Genome-wide association and linkage study in the Amish detects a novel candidate late-onset Alzheimer disease gene. Ann. Hum. Genet. 2012 Sep; 76(5): 342-51. PMID: 22881374, PMCID: PMC3419486, DOI: 10.1111/j.1469-1809.2012.00721.x, ISSN: 1469-1809.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22881374.
  • Cooperstein E, Gilbert J, Epstein JB, Dietrich MS, Bond SM, Ridner SH, Wells N, Cmelak A, Murphy BA. Vanderbilt Head and Neck Symptom Survey version 2.0: report of the development and initial testing of a subscale for assessment of oral health. Head Neck [print-electronic]. 2012 Jun; 34(6): 797-804. PMID: 22127786, DOI: 10.1002/hed.21816, ISSN: 1097-0347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22127786.
  • Compton DL, Gilbert JK, Jenkins JR, Fuchs D, Fuchs LS, Cho E, Barquero LA, Bouton B. Accelerating chronically unresponsive children to tier 3 instruction: what level of data is necessary to ensure selection accuracy?. J Learn Disabil [print-electronic]. 2012 May; 45(3): 204-16. PMID: 22491810, PII: 0022219412442151, DOI: 10.1177/0022219412442151, ISSN: 1538-4780.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22491810.
  • Gilbert J, Rudek MA, Higgins MJ, Zhao M, Bienvenu S, Tsottles N, Chaudhry MA, Wahl R, Forastiere A, Gillison M. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck. Clin. Cancer Res [print-electronic]. 2012 Mar 3/15/2012; 18(6): 1735-42. PMID: 22271880, PMCID: PMC3306472, PII: 1078-0432.CCR-11-2544, DOI: 10.1158/1078-0432.CCR-11-2544, ISSN: 1078-0432.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22271880.
  • Preininger AM, Kaya AI, Gilbert JA, Busenlehner LS, Armstrong RN, Hamm HE. Myristoylation exerts direct and allosteric effects on Ga conformation and dynamics in solution. Biochemistry [print-electronic]. 2012 Mar 3/6/2012; 51(9): 1911-24. PMID: 22329346, PMCID: PMC3312377, DOI: 10.1021/bi201472c, ISSN: 1520-4995.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/22329346.
  • Gilbert J, Haman KL, Dietrich MS, Blakely RD, Shelton RC, Murphy BA. Depression in patients with head and neck cancer and a functional genetic polymorphism of the serotonin transporter gene. Head Neck [print-electronic]. 2012 Mar; 34(3): 359-64. PMID: 21604315, DOI: 10.1002/hed.21744, ISSN: 1097-0347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21604315.
  • Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer [print-electronic]. 2012 Feb 2/15/2012; 118(4): 1007-13. PMID: 21766301, DOI: 10.1002/cncr.26364, ISSN: 1097-0142.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21766301.
  • Horn L, Koehler E, Gilbert J, Johnson DH. Factors associated with the career choices of hematology and medical oncology fellows trained at academic institutions in the United States. J. Clin. Oncol [print-electronic]. 2011 Oct 10/10/2011; 29(29): 3932-8. PMID: 21911716, PMCID: PMC3189092, PII: JCO.2011.35.8663, DOI: 10.1200/JCO.2011.35.8663, ISSN: 1527-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21911716.
  • Gilbert JK, Compton DL, Kearns DM. Word and Person Effects on Decoding Accuracy: A New Look at an Old Question. J Educ Psychol. 2011 May 5/1/2011; 103(2): 489-507. PMID: 21743750, PMCID: PMC3129854, DOI: 10.1037/a0023001, ISSN: 0022-0663.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/21743750.
  • Diaz R, Jaboin JJ, Morales-Paliza M, Koehler E, Phillips JG, Stinson S, Gilbert J, Chung CH, Murphy BA, Yarbrough WG, Murphy PB, Shyr Y, Cmelak AJ. Hypothyroidism as a consequence of intensity-modulated radiotherapy with concurrent taxane-based chemotherapy for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys [print-electronic]. 2010 Jun 6/1/2010; 77(2): 468-76. PMID: 19577867, PII: S0360-3016(09)00764-0, DOI: 10.1016/j.ijrobp.2009.05.018, ISSN: 1879-355X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19577867.
  • Compton DL, Fuchs D, Fuchs LS, Bouton B, Gilbert JK, Barquero LA, Cho E, Crouch RC. Selecting At-Risk First-Grade Readers for Early Intervention: Eliminating False Positives and Exploring the Promise of a Two-Stage Gated Screening Process. J Educ Psychol. 2010 May 5/1/2010; 102(2): 327-40. PMID: 20689725, PMCID: PMC2913521, DOI: 10.1037/a0018448, ISSN: 0022-0663.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20689725.
  • Chung CH, Aulino J, Muldowney NJ, Hatakeyama H, Baumann J, Burkey B, Netterville J, Sinard R, Yarbrough WG, Cmelak AJ, Slebos RJ, Shyr Y, Parker J, Gilbert J, Murphy BA. Nuclear factor-kappa B pathway and response in a phase II trial of bortezomib and docetaxel in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann. Oncol [print-electronic]. 2010 Apr; 21(4): 864-70. PMID: 19850643, PMCID: PMC2844946, PII: mdp390, DOI: 10.1093/annonc/mdp390, ISSN: 1569-8041.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19850643.
  • Chung CH, Seeley EH, Roder H, Grigorieva J, Tsypin M, Roder J, Burtness BA, Argiris A, Forastiere AA, Gilbert J, Murphy B, Caprioli RM, Carbone DP, Cohen EE. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients. Cancer Epidemiol. Biomarkers Prev [print-electronic]. 2010 Feb; 19(2): 358-65. PMID: 20086114, PMCID: PMC2846615, PII: 1055-9965.EPI-09-0937, DOI: 10.1158/1055-9965.EPI-09-0937, ISSN: 1538-7755.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20086114.
  • Murphy BA, Dietrich MS, Wells N, Dwyer K, Ridner SH, Silver HJ, Gilbert J, Chung CH, Cmelak A, Burkey B, Yarbrough WG, Sinard R, Netterville J. Reliability and validity of the Vanderbilt Head and Neck Symptom Survey: a tool to assess symptom burden in patients treated with chemoradiation. Head Neck. 2010 Jan; 32(1): 26-37. PMID: 19626644, DOI: 10.1002/hed.21143, ISSN: 1097-0347.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19626644.
  • Hatakeyama H, Cheng H, Wirth P, Counsell A, Marcrom SR, Wood CB, Pohlmann PR, Gilbert J, Murphy B, Yarbrough WG, Wheeler DL, Harari PM, Guo Y, Shyr Y, Slebos RJ, Chung CH. Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS ONE. 2010; 5(9): e12702. PMID: 20856931, PMCID: PMC2938338, DOI: 10.1371/journal.pone.0012702, ISSN: 1932-6203.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/20856931.
  • Schnetz-Boutaud NC, Anderson BM, Brown KD, Wright HH, Abramson RK, Cuccaro ML, Gilbert JR, Pericak-Vance MA, Haines JL. Examination of tetrahydrobiopterin pathway genes in autism. Genes Brain Behav [print-electronic]. 2009 Nov; 8(8): 753-7. PMID: 19674121, PMCID: PMC2784255, PII: GBB521, DOI: 10.1111/j.1601-183X.2009.00521.x, ISSN: 1601-183X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19674121.
  • Yang ES, Murphy BM, Chung CH, Netterville JL, Burkey BB, Gilbert J, Yarbrough WG, Sinard R, Cmelak AJ. Evolution of clinical trials in head and neck cancer. Crit. Rev. Oncol. Hematol [print-electronic]. 2009 Jul; 71(1): 29-42. PMID: 18996026, PII: S1040-8428(08)00244-8, DOI: 10.1016/j.critrevonc.2008.09.015, ISSN: 1879-0461.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18996026.
  • Murphy BA, Gilbert J. Dysphagia in head and neck cancer patients treated with radiation: assessment, sequelae, and rehabilitation. Semin Radiat Oncol. 2009 Jan; 19(1): 35-42. PMID: 19028344, PII: S1053-4296(08)00062-3, DOI: 10.1016/j.semradonc.2008.09.007, ISSN: 1532-9461.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19028344.
  • Anderson BM, Schnetz-Boutaud N, Bartlett J, Wright HH, Abramson RK, Cuccaro ML, Gilbert JR, Pericak-Vance MA, Haines JL. Examination of association to autism of common genetic variationin genes related to dopamine. Autism Res. 2008 Dec; 1(6): 364-9. PMID: 19360691, PMCID: PMC2947794, DOI: 10.1002/aur.55, ISSN: 1939-3806.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/19360691.
  • Gilbert J, Cmelak A, Shyr Y, Netterville J, Burkey BB, Sinard RJ, Yarbrough WG, Chung CH, Aulino JM, Murphy BA. Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck. Cancer. 2008 Jul 7/1/2008; 113(1): 186-92. PMID: 18484593, DOI: 10.1002/cncr.23545, ISSN: 0008-543X.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18484593.
  • Slebos RJ, Li M, Vadivelu S, Burkey BB, Netterville JL, Sinard R, Gilbert J, Murphy B, Chung CH, Shyr Y, Yarbrough WG. Microsatellite mutations in buccal cells are associated with aging and head and neck carcinoma. Br. J. Cancer [print-electronic]. 2008 Feb 2/12/2008; 98(3): 619-26. PMID: 18212747, PMCID: PMC2243146, PII: 6604198, DOI: 10.1038/sj.bjc.6604198, ISSN: 0007-0920.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/18212747.
  • Murphy BA, Gilbert J, Cmelak A, Ridner SH. Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol. 2007 Oct; 5(10): 807-22. PMID: 17998898, ISSN: 1543-0790.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17998898.
  • Murphy BA, Gilbert J, Ridner SH. Systemic and global toxicities of head and neck treatment. Expert Rev Anticancer Ther. 2007 Jul; 7(7): 1043-53. PMID: 17627463, DOI: 10.1586/14737140.7.7.1043, ISSN: 1744-8328.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17627463.
  • Gilbert J, Argiris A. Emerging molecular targeted therapies in squamous cell carcinoma of the head and neck. Clin Adv Hematol Oncol. 2006 Aug; 4(8): 611-9. PMID: 17099619, ISSN: 1543-0790.
    Available from: http://www.ncbi.nlm.nih.gov/pubmed/17099619.